Company Encyclopedia
View More
name
CHINARES PHARMA
03320.HK
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies.
1.390 T
03320.HKMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking17/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE5.69%C
    • Profit Margin1.08%C
    • Gross Margin16.31%D
  • Growth ScoreC
    • Revenue YoY4.33%C
    • Net Profit YoY-25.77%D
    • Total Assets YoY9.70%B
    • Net Assets YoY17.51%A
  • Cash ScoreB
    • Cash Flow Margin9320.07%A
    • OCF YoY4.33%C
  • Operating ScoreA
    • Turnover0.94A
  • Debt ScoreD
    • Gearing Ratio60.94%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CHINARES PHARMA's DC6001 tablets and metronidazole gel approved for clinical use and market launch

    CHINARES PHARMA announced that its subsidiary Beijing Shuanghe Runchuang Technology's DC6001 tablets have received clinical trial approval from the National Medical Products Administration for the treatment of hereditary macular degeneration in adolescents. At the same time, the metronidazole gel of China Resources Sanjiu Pharmaceutical Co., Ltd. has been approved for market launch, suitable for local treatment of various skin inflammations

    AASTOCKS·
    HK
    03320
    -1.10%
    AASTOCKS·
    HK
    03320
    -1.10%

    Two products under CHINARES PHARMA have been included in the national medical insurance catalog

    CHINARES PHARMA announced that its Yiqi Qingfei Granules and Methylphenidate Hydrochloride Sustained-Release Capsules have been included in the recently released "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)." Yiqi Qingfei Granules are specifically aimed at the comprehensive symptoms during the recovery period of various respiratory infection diseases. Methylphenidate Hydrochloride Sustained-Release Capsules are used for the treatment of Attention Deficit Hyperactivity Disorder in children aged 6 and above. Both products were approved for market launch in January of this year

    AASTOCKS·
    HK
    03320
    -1.10%
    AASTOCKS·
    HK
    03320
    -1.10%

    Morning Trend | CHINARES PHARMA consolidates with reduced volume, is a breakout imminent?

    Yesterday, China Resources Pharmaceutical (3320.HK) maintained a low-volume oscillating trend, with the stock price gradually dipping towards the 30-day moving average. Pharmaceutical stocks have recently been in a weak range, with overall capital showing an outflow pattern, and defensive allocation preferences dominating. As the national medical insurance negotiation phase approaches, there is a lack of significant positive news, and some major players are choosing to remain inactive or reduce holdings in advance, leading to a spread of wait-and-see sentiment. From a technical perspective, the MACD daily structure has shown a clear death cross, with short-term momentum leaning bearish. The 5-day and 10-day moving averages are stuck in a stalemate, indicating weak bullish momentum and a slight advantage for the bears. Throughout the day, net capital flow slightly outflowed, further indicating that major players have no intention of deep involvement in the short term. Considering the strong sensitivity of the pharmaceutical sector to news, future events such as medical insurance price adjustments and generic drug bidding may become important catalysts for short-term breakthroughs, which need to be closely monitored. Currently, China Resources Pharmaceutical maintains a box oscillation pattern. If there are clear policy developments or if the pharmaceutical sector shows new incremental movements, it could become a point for right-side capital to test new actions. However, the operational nodes remain unclear, and the sector carries significant risks; any blind chasing of price increases can easily increase risk exposure. There are high requirements for position management, and close attention should be paid to intraday trading and position changes, adjusting response strategies in conjunction with policy signals. In summary, although China Resources Pharmaceutical is under short-term pressure, the adjustment range is gradually approaching a relatively supportive area

    Technical Forecast·
    HK
    03320
    -1.10%
    Technical Forecast·
    HK
    03320
    -1.10%

    CHINARES PHARMA announced that its Type 2 diabetes drug has received a notice of approval for a supplemental drug application

    CHINARES PHARMA announced that its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for Pioglitazone Hydrochloride Dispersible Tablets, which is regarded as passing the consistency evaluation. Pioglitazone Hydrochloride Dispersible Tablets are used for the treatment of type 2 diabetes

    AASTOCKS·
    HK
    03320
    -1.10%
    AASTOCKS·
    HK
    03320
    -1.10%

    CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

    China Resources Pharmaceutical announced that its subsidiary, CR Sanjiu, has obtained implied permission for clinical trials of its pediatric calming and brain-nourishing granules. This product was jointly developed by CR Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a Category 1.1 new drug in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied permission for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

    AASTOCKS·
    SZ
    000999
    -0.04%
    HK
    03320
    -1.10%
    AASTOCKS·
    SZ
    000999
    -0.04%
    HK
    03320
    -1.10%
    © 2025 Longbridge｜Disclaimer